TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.
Abstract
1011 Background: Chemotherapy is a standard of care for TNBC despite its suboptimal efficacy. ≈15–20% of TNBC have BRCA1/2 mutations (mut); ≈75% of BRCA1 mut BCs are TN. Single agent poly(ADP-ribose) polymerase (PARP) inhibitors have clinical activity in pts with BRCA1/2 mutations (BRCAmut) BC and provide median PFS of 6 mos in pts with BRCAmut TNBC vs 3.5 mos for chemotherapy. Single-agent pembrolizumab (pembro), a programmed death 1(PD–1) inhibitor, has shown objective response rates (ORR) of 5–18% in previously treated TNBC. TOPACIO (NCT02657889) is a fully enrolled study evaluating the safety and efficacy of combination treatment with selective PARP1/2 inhibitor niraparib + pembro in pts with met TNBC. Methods: Pts received niraparib 200 mg orally once daily + pembro 200 mg IV on day 1 of each 21-day cycle. Primary efficacy endpoint was ORR and secondary endpoints included disease control rate (DCR = CR+PR+SD [stable disease]). Results: As of Jan 2018, 12 of 54 enrolled TNBC pts (22%) had deleterious BRCAmut; 9 (17%) not tested/indeterminate results. Median age was 54 yrs, with median of 1 prior line of therapy in the met setting (range 0–3); 22 (41%) had received prior platinum in the met setting; 39 (72%) had received prior (neo)adjuvant therapy. Forty-five pts were evaluable, with ≥1 on-study scan. To date, ORR is 29% and DCR is 49%, including 3 CR (7%), 10 PR (22%), 9 SD (20%), and 23 progressive disease (PD) (51%). Ten of 13 responders have ongoing responses; 13 pts have received > 6 mos of treatment (6 BRCAmut, 5 BRCAwt, 2 BRCAunk); 11 pts remain on treatment. The 12 BRCAmut pts were 1 CR, 7 PR, 1 SD and 3 PD. Median PFS in BRCAmut group is 8.1 mos (95% CI 0.2–NE). ORR (any BRCA status) was 33% in PD-L1-pos (combined proportion score ≥1%) vs 15% in PD-L1-neg pts. Treatment-related grade ≥3 AEs occurred in 27 pts (50%); most common were thrombocytopenia (13%) & anemia (11%). Follow-up is ongoing. Conclusions: Preliminary activity is encouraging with durable responses observed irrespective of BRCA1/2 or PD-L1 status or prior platinum exposure with the highest ORR in BRCAmut pts. No new safety signals were identified with the combination. Clinical trial information: NCT02657889. ORR DCR TNBC overall, n = 45 29% 49% TNBC BRCAmut, n = 12 67% 75%
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Accumulating evidence indicates that PARPi plus α-PD-1/PD-L1 is a promising combination strategy in multiple types of cancers, including metastatic castrate-resistant prostate cancer and metastatic TNBC.
“Accumulating evidence indicates that PARPi plus α-PD-1/PD-L1 is a promising combination strategy in multiple types of cancers, including metastatic castrate-resistant prostate cancer and metastatic TNBC [230, 231].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [231]
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
“Subsequently, the FDA approved atezolizumab plus chemotherapy for TNBC (atezolizumab plus nab-paclitaxel, based on IMpassion130), SCLC (atezolizumab plus carboplatin and etoposide, based on IMpower133), and non-squamous NSCLC (atezolizumab plus nab-paclitaxel and carboplatin, based on IMpower130) [66–68].”
BackgroundInfluentialEmens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C. T., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 775 · see citing works
“(%) [95% CI] 5 (24) [8-47] 10 (11) [5-19] 0 [0-17] 15 (16) [10-26]”
Self-citationPantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743 · see citing works
“Notably, the majority of TNBC clinical responses to niraparib/pembrolizumab occurred among patients harboring BRCA mutations (6).”
BackgroundImmunotherapy and targeted therapy combinations in metastatic breast cancer
Esteva, F. J., Hubbard-Lucey, V. M., Tang, J., & Pusztai, L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30026-9 · Cited by 452 · see citing works
Current Landscape of Immunotherapy in Breast Cancer: A Review
Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7147 · Cited by 384 · see citing works
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 352 · see citing works
Development of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 336 · see citing works
Development of PARP and immune-checkpoint inhibitor combinations
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239 · see citing works
Recent therapeutic trends and promising targets in triple negative breast cancer
Hwang, S., Park, S., & Kwon, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.006 · Cited by 233 · see citing works
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Planes-Laine, G., Rochigneux, P., Bertucci, F., Chrétien, A.-S., Viens, P., Sabatier, R., & Gonçalvès, A. (2019) · Cancers · doi:10.3390/cancers11071033 · Cited by 220 · see citing works
“…and with no more than 2 lines of chemotherapy for advanced disease (including platinum, provided that no progression was observed while on or within 8 weeks of the last platinum), received oral niraparib at 200 mg / day continuously in combination with IV pembrolizumab at 200 mg every 3 weeks [79].”
MethodPARP Inhibition in Cancer: An Update on Clinical Development
Sachdev, E., Tabatabai, R., Roy, V. Y., Rimel, B. J., & Mita, M. M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00680-2 · Cited by 184 · see citing works
Self-citationTherapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179 · see citing works
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143 · see citing works
Parikh, A. R., He, Y., Hong, T. S., Corcoran, R. B., Clark, J. W., Ryan, D. P., Zou, L., Ting, D. T., Catenacci, D. V. T., Chao, J., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0034 · Cited by 92 · see citing works
“Trials are underway in gynecologic, breast, and genitourinary cancers with signals of activity [31, 44, 45].”
BackgroundTwo may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
Page, D. B., Bear, H. D., Prabhakaran, S., Gatti-Mays, M. E., Thomas, A., Cobain, E. F., McArthur, H. L., Balko, J. M., Gameiro, S. R., Nanda, R., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0130-x · Cited by 84 · see citing works
Therapeutic Targeting of DNA Damage Response in Cancer
Choi, W., & Lee, E. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031701 · Cited by 91 · see citing works
“Although the efficacy was low for SCLC and modest for TNBC, prexasertib showed promising efficacy in ovarian cancer.”
BackgroundInfluentialEmens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 84 · see citing works
Self-citationPARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
Boussios, S., Karathanasi, A., Cooke, D., Neille, C., Sadauskaite, A., Moschetta, M., Zakynthinakis-Kyriakou, N., & Pavlidis, N. A. (2019) · Diagnostics · doi:10.3390/diagnostics9020055 · Cited by 80 · see citing works
Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges
Gagliato, D. D. M., Buzaid, A. C., Pérez-García, J. M., & Cortés, J. (2020) · BioDrugs · doi:10.1007/s40259-020-00436-9 · Cited by 64 · see citing works
“Response rate was considerably higher in PD-L1-positive patients: 33% in PD-L1-positive versus 15% in PD-L1-negative patients [29, 30].”
BackgroundSun, W., Zhang, Q., Wang, R., Yang, L., Sun, Y., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648687 · Cited by 61 · see citing works
Bergholz, J. S., Wang, Q., Kabraji, S. K., & Zhao, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2300 · Cited by 61 · see citing works
Recent advancements in PARP inhibitors-based targeted cancer therapy
Zhou, P., Wang, J. L., Mishail, D., & Wang, C. (2020) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaa030 · Cited by 50 · see citing works
PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
Murthy, P., & Muggia, F. M. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.002 · Cited by 46 · see citing works
“Monotherapy versus combination therapy Preclinical and some clinical data indicate that immune checkpoint inhibition may synergize with PARP inhibition in tumors with HRD, and that tumors with defective DNA repair are especially sensitive to immunotherapy([75-77]).”
BackgroundTelli, M. L., Chu, C., Badve, S., Vinayak, S., Silver, D. P., Isakoff, S. J., Kaklamani, V., Gradishar, W. J., Stearns, V., Connolly, R. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0664 · Cited by 45 · see citing works
Self-citationGadag, S., Sinha, S., Nayak, Y., Garg, S., & Nayak, U. Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060524 · Cited by 46 · see citing works
“Novel targeted therapies using poly (ADP-ribose) polymerase (PARP) inhibitors such as talazoparib, olaparib, and niraparib, in combination with immune checkpoint inhibitors, have shown positive clinical outcomes in patients [74,75].”
BackgroundGupta, M., Iyer, R. V., & Fountzilas, C. K. (2019) · Cancers · doi:10.3390/cancers11121980 · Cited by 39 · see citing works
“Combination of niraparib and pembrolizumab in a phase II trial (TOPACIO/Keynote-162) in triple negative breast cancer (TNBC) and recurrent ovarian cancer patients showed that the combination is safe and effective, irrespective of the platinum exposure or BRCA 1/2 or PD-L1 status [100,101].”
BackgroundThe DNA damage response network in the treatment of head and neck squamous cell carcinoma
Psyrri, A. K., Gkotzamanidou, M. A., Papaxoinis, G., Krikoni, L., Economopoulou, P., Kotsantis, I., Anastasiou, Μ., & Souliotis, V. L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100075 · Cited by 41 · see citing works
Zhao, J., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000710 · Cited by 39 · see citing works
“The KEYNOTE-162/TOPACIO trial investigated the effects of a combination of niraparib and pembrolizumab in patients with metastatic TNBC regardless of the BRCA status.([103]) The ORR and DCR for all the patients was 29% and 49%, respectively.”
BackgroundTan, E. S., & Şahin, İ. H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1886077 · Cited by 37 · see citing works
Update on Precision Medicine in Breast Cancer
Sachdev, J. C., Sandoval, A. C., & Jahanzeb, M. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_2 · Cited by 37 · see citing works
Optimizing poly ( ADP ‐ribose) polymerase inhibition through combined epigenetic and immunotherapy
Prasanna, T., Wu, F., Khanna, K. K., Yip, D., Malik, L., Dahlstrom, J. E., & Rao, S. (2018) · Cancer Science · doi:10.1111/cas.13799 · Cited by 34 · see citing works
Lamberti, G., Andrini, E., Sisi, M., Federico, A. D., & Ricciuti, B. (2020) · Future Oncology · doi:10.2217/fon-2020-0215 · Cited by 34 · see citing works
Macchini, M., Centonze, F., Peretti, U., Orsi, G., Militello, A. M., Valente, M. M., Cascinu, S., & Reni, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102262 · Cited by 33 · see citing works
Jungles, K. M., Holcomb, E. A., Pearson, A. N., Jungles, K. R., Bishop, C. R., Pierce, L. J., Green, M. D., & Speers, C. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022542 · Cited by 35 · see citing works
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Mohan, R. R., Drokhlyansky, E., Wittenberghe, N. V., Ashenberg, O., Farhi, S. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.267336 · Cited by 33 · see citing works
Immunotherapy in Triple-Negative Breast Cancer: Present and Future
Kim, I., Sanchez, K. G., McArthur, H. L., & Page, D. B. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00345-z · Cited by 33 · see citing works
Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer
Savard, M.-F., Khan, O. F., Hunt, K. K., & Verma, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237419 · Cited by 31 · see citing works
Present and Future of Immunotherapy for Triple-Negative Breast Cancer
Sriramulu, S., Thoidingjam, S., Speers, C. W., & Nyati, S. (2024) · Cancers · doi:10.3390/cancers16193250 · Cited by 28 · see citing works
“Comparing the results of the phase-II KEYNOTE-162 trial [121], which combined PD-1 checkpoint inhibitor pembrolizumab with PARPi niraparib, to trials with PARPi monotherapy, it became evident that patients with BRCA1 or BRCA2 pathogenic variants (PVs) displayed long-lasting responses with…”
ResultShi, J., Liu, F., & Song, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s272685 · Cited by 26 · see citing works
“Moreover, 50% of patients had grade ≥3 TRAEs, thrombocytopenia, and anemia.(90) Liu et al initially reported the antitumor activity of anti-PD-1 antibody”
BackgroundEmerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
Cipriano, É., & Mesquita, A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234211002491 · Cited by 26 · see citing works
Li, H., Chang, Y., Jin, T., & Zhang, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03769-z · Cited by 23 · see citing works
“TOPACIO [35] explored the use of a monoclonal antibody against pembrolizumab + the PARP inhibitor niraparib for the treatment of advanced TNBC.”
Sambade, M. J., Swearingen, A. E. D. V., McClure, M. B., Deal, A. M., Santos, C., Sun, K., Wang, J., Mikule, K. W., & Anders, C. K. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz005 · Cited by 22 · see citing works
“16, 17 Specific to metastatic TNBC, the results of the TOPACIO study illustrated a 28% objective response rate and progression-free survival of 8.3 months for those whose tumors harbored a BRCA mutation.”
InfluentialSelf-citationZhang, K., Chen, L., Zheng, H., & Zeng, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09959-6 · Cited by 22 · see citing works
Hachem, G. E., Gombos, A., & Awada, A. H. (2019) · F1000Research · doi:10.12688/f1000research.17542.1 · Cited by 19 · see citing works
Clinical Data on Immunotherapy in Breast Cancer
Radosa, J. C., Stotz, L., Müller, C., Kaya, A. C., Solomayer, E., & Radosa, M. P. (2020) · Breast Care · doi:10.1159/000511788 · Cited by 17 · see citing works
Cerniglia, M., Xiu, J., Grothey, A., Pishvaian, M. J., Baca, Y., Hwang, J. J., Marshall, J. L., VanderWalde, A. M., Shields, A. F., Lenz, H.-J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0879 · Cited by 16 · see citing works
Keup, C., Kimmig, R., & Kasimir‐Bauer, S. (2020) · Breast Care · doi:10.1159/000510509 · Cited by 15 · see citing works
Ledys, F., Kalfeist, L., Galland, L., Limagne, E., & Ladoire, S. (2021) · Cancers · doi:10.3390/cancers13235999 · Cited by 16 · see citing works
“The phase II Keynote‐162/TOPACIO study evaluated the effect of a combination of niraparib and pembrolizumab in mTNBC [67] (NCT02657889).”
BackgroundInfluentialAraghi, M., Gharebakhshi, F., Faramarzi, F., Mafi, A., Mousavi, T., Alimohammadi, M., & Soleimantabar, H. (2024) · Current Gene Therapy · doi:10.2174/0115665232283880240301035621 · Cited by 15 · see citing works
Murthy, P., & Muggia, F. M. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.904 · Cited by 16 · see citing works
“The overall response rate for all patients was 29% and was significantly higher in the patients with BRCA mutations [103].”
BackgroundChimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review
Sharma, R., Suravarjhula, L., Banerjee, M., Kumar, G., & Kumar, N. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230220092125 · Cited by 13 · see citing works
Tahir, I. M., Rauf, A., Mehboob, H., Sadaf, S., Alam, M. S., Kalsoom, F., Bouyahya, A., Allam, A. E., Omari, N. E., Bakrim, S., et al. (2022) · Human Antibodies · doi:10.3233/hab-220001 · Cited by 12 · see citing works
“(33 percent vs 15 percent) [143].”
Novel classes of immunotherapy for breast cancer
Hernando‐Calvo, A., Cescon, D. W., & Bedard, P. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06405-2 · Cited by 11 · see citing works
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment
Catalano, M., Iannone, L. F., Cosso, F., Generali, D., Mini, E., & Roviello, G. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2158813 · Cited by 12 · see citing works
Vikas, P., Korde, L. A., Somerfield, M. R., & Hershman, D. L. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00284 · Cited by 10 · see citing works
Developing combination therapies with biologics in triple-negative breast cancer
Gaudio, G., Martino, E., Pellizzari, G., Cavallone, M., Castellano, G., Omar, A. A., Katselashvili, L., Trapani, D., & Curigliano, G. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2408756 · Cited by 8 · see citing works
“The TOPACIO/ KEYNOTE-162 Phase I/II study evaluated the combination of niraparib and pembrolizumab for mTNBC, showing prelimin-ary encouraging activity both in BRCA mutant and overall population [71].”
Trusler, O., Goodwin, J., & Laslett, A. L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188459 · Cited by 8 · see citing works
Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer
Morganti, S., & Tolaney, S. M. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.08.014 · Cited by 5 · see citing works
Self-citationMichael, A., Wilson, W., Sunshine, S., et al. (2024) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-005200 · Cited by 5 · see citing works
Olson, B. M., & Patnaik, A. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.11.009 · Cited by 5 · see citing works
“This agrees with results seen evaluating this combination in other malignancies, including preliminary results from the TOPACIO/Keynote-162 trial in breast and ovarian cancer (NCT02657889), in which PARPi in combination with checkpoint blockade led to durable clinical responses (including higher response rates in pati…”
ResultPARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer
Desai, D., Khandwala, P., Parsi, M., & Potdar, R. R. (2021) · Medical Oncology · doi:10.1007/s12032-021-01507-9 · Cited by 5 · see citing works
Matossian, M. D., Chen, N., & Nanda, R. (2023) · Current Breast Cancer Reports · doi:10.1007/s12609-023-00492-4 · Cited by 4 · see citing works
Ghafouri, S. R., Guvvala, S. L., Jones, C., & Philipovskiy, A. V. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002298 · Cited by 4 · see citing works
Immune checkpoint inhibition in early-stage triple-negative breast cancer
Varma, R., Wright, M., Abraham, J., & Kruse, M. L. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2139240 · Cited by 5 · see citing works
PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use
Dolgasheva, D. S., Певзнер, А. М., Ibragimova, M. K., et al. (2020) · Tumors of female reproductive system · doi:10.17650/1994-4098-2020-16-1-55-64 · Cited by 3 · see citing works
Vankina, R., & Yuan, Y. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_13 · Cited by 2 · see citing works
DNA damage targeted therapy for advanced breast cancer
Patel, V., Casimiro, S., Abreu, C., Barroso, T., Sousa, R., Torres, S., Ribeiro, L., Nogueira-Costa, G., Pais, H. L., Pinto, C., et al. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00241 · Cited by 3 · see citing works
Trials of Immunotherapy in Triple Negative Breast Cancer
Gümüşay, Ö., Wabl, C. A., & Rugo, H. S. (2021) · Current Breast Cancer Reports · doi:10.1007/s12609-021-00418-y · Cited by 2 · see citing works
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
Петровна, Г. И., Гордеева, О. О., & Manukyan, M. S. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2020.4.200495 · Cited by 2 · see citing works
IMMUNE CHECKPOINT BLOCKADE IN BREAST CANCER THERAPY
Hromakova, I. А., Сорочан, П. П., Prokhach, N. E., et al. (2020) · International Medical Journal · doi:10.37436/2308-5274-2020-1-7 · Cited by 1 · see citing works
Fine-Tuning Immunotherapy in MMR-D/MSI-H Colorectal Cancer
Şahin, İ. H. (2019) · Colorectal Cancer · doi:10.2217/crc-2019-0014 · Cited by 1 · see citing works
Xie, R. (2021) · Trends in Immunotherapy · doi:10.24294/ti.v5.i2.1.1372 · Cited by 1 · see citing works
“Till now, only three PARP inhibitor/anti-PD-1/ L1 combos have been studied: olaparib/durvalumab([26,27]), niraparib/pbrobrolizumab([28,29]), and BGB-A 317/BGB-290([30]).”
BackgroundStandard changing news der Senologie und der Gynäkologischen Onkologie 2018
Preuß, C., Heindl, F., Jud, S. M., Hein, A., Hack, C. C., Beckmann, M. W., Lux, M. P., & Rauh, C. (2018) · Der Klinikarzt · doi:10.1055/a-0805-3978
“Aktuell läuft zudem ein Studienkonzept, welches den Einsatz von selektiven PARP-Inhibitoren beim HER2-negativen Mammakarzinom mit homologer rekombinanter Defizienz (HRD) [BRCA1/2-Mutation oder hoher HRD-Score] im Vergleich zur platinhaltigen Chemotherapie und anschließender Behandlung mit Epirubicin und Cyclophosphami…”
BackgroundInfluentialDie systemische Behandlung des triple-negativen Mammakarzinoms
Landin, J., & Vetter, M. H. F. (2019) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-019-6471-7
Tan, Y., & Song, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24452
“Specifically, majority of the clinical trials have examined that such combined strategies have tolerance for patients and are effective in several tumor types, including breast cancers [41 – 44], ovarian cancers [45,46], and prostate cancers [47].”
Background
- Authors
- Vinayak, S., Tolaney, S. M., Schwartzberg, L. S., Mita, M. M., McCann, G. A.-L., Tan, A. R., Wahner Hendrickson, A. E., Forero-Torres, A., Anders, C. K., Wulf, G. M., Dillon, P. M., Lynce, F., Zarwan, C., Erban, J. K., Dezube, B. J., Zhou, Y., Buerstatte, N., Arora, S., Achour, H., & Telli, M. L.
- Affiliations
- Case Comprehensive Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- The West Clinic, Memphis, TN;
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Levine Cancer Institute (US)
- Mayo Clinic Rochester, Rochester, MN;
- University of Alabama at Birmingham, Birmingham, AL;
- University of North Carolina at Chapel Hill (US)
- Beth Israel Deaconess Medical Center (US)
- University of Virginia (US)
- MedStar Georgetown University Hospital (US)
- Lahey Hospital and Medical Center (US)
- Tufts Medical Center (US)
- Tesaro (United States) (US)
- Stanford University (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2018-05-20
- Volume
- 36
- Issue
- 15_suppl
- Pages
- 1011-1011
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2807543909
- Cited by
- 77
- References
- 0
- Citations by year
- 2025: 1 · 2024: 7 · 2023: 2 · 2022: 11 · 2021: 14 · 2020: 14 · 2019: 23 · 2018: 5
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
- Keywords
- niraparib, pembrolizumab, metastatic triple-negative breast cancer, PARP inhibitors, PD-1 inhibitors, BRCA mutations, combination immunotherapy, objective response rate, disease control rate, platinum-refractory disease, safety and tolerability, immune-related adverse events, PD-L1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
